KemPharm Inc - ESG Rating & Company Profile powered by AI
If you are employed by KemPharm Inc and you would like to licence your ESG aseessment, please contact us. Detailed ESG assessment of KemPharm Inc are accessed by signing in. The Disclosure score covers 17 UN SDGs including: 'Affordable & Clean Energy', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'.
KemPharm Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 0.0 and governance score of 3.2.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | KemPharm Inc | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does KemPharm Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes KemPharm Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes KemPharm Inc report the average age of the workforce?
Sign up for free to unlockDoes KemPharm Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes KemPharm Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes KemPharm Inc disclose cybersecurity risks?
Sign up for free to unlockDoes KemPharm Inc offer flexible work?
Sign up for free to unlockDoes KemPharm Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes KemPharm Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes KemPharm Inc conduct supply chain audits?
Sign up for free to unlockDoes KemPharm Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes KemPharm Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes KemPharm Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes KemPharm Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes KemPharm Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes KemPharm Inc disclose water use targets?
Sign up for free to unlockDoes KemPharm Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid KemPharm Inc have a product recall in the last two years?
Sign up for free to unlockDoes KemPharm Inc disclose incidents of discrimination?
Sign up for free to unlockDoes KemPharm Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas KemPharm Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes KemPharm Inc disclose parental leave metrics?
Sign up for free to unlockDoes KemPharm Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes KemPharm Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes KemPharm Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes KemPharm Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes KemPharm Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes KemPharm Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs KemPharm Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes KemPharm Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes KemPharm Inc disclose its waste policy?
Sign up for free to unlockDoes KemPharm Inc report according to TCFD requirements?
Sign up for free to unlockDoes KemPharm Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes KemPharm Inc disclose energy use targets?
Sign up for free to unlockDoes KemPharm Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes KemPharm Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for KemPharm Inc
These potential risks are based on the size, segment and geographies of the company.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.